L Porcelli
Overview
Explore the profile of L Porcelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Porcelli L, Stolfa D, Stefanachi A, Di Fonte R, Garofoli M, Iacobazzi R, et al.
Cancer Lett
. 2018 Dec;
445:1-10.
PMID: 30583077
We previously demonstrated that some N-biphenylanilides caused cell-cycle arrest at G2/M transition in breast cancer cells. Among them we choose three derivatives, namely PTA34, PTA73 and RS35 for experimentation in...
2.
De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, et al.
Cell Death Dis
. 2014 Feb;
5:e1076.
PMID: 24556691
Understanding of BRCA1/2 interaction with the base excision repair (BER) pathway could improve therapy based on 'synthetic lethality', whose effectiveness is based on homologous recombination deficiency in cells lacking functional...
3.
Quatrale A, Porcelli L, Gnoni A, Numico G, Paradiso A, Azzariti A
Curr Med Chem
. 2013 Sep;
21(8):1039-49.
PMID: 23992324
Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new...
4.
Porcelli L, Quatrale A, Mantuano P, Silvestris N, Rolland J, Biancolillo L, et al.
Curr Pharm Des
. 2012 Sep;
19(5):918-26.
PMID: 22973960
Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations...
5.
Porcelli L, Quatrale A, Mantuano P, Silvestris N, Brunetti A, Calvert H, et al.
Curr Med Chem
. 2012 Jul;
19(23):3858-73.
PMID: 22788762
A large body of evidence point out that the onset of synthetic lethality may provide a useful tool for amplifying the efficacy of drugs in anticancer regimens, to uncover interdependence...
6.
Porcelli L, Gilardi F, Laghezza A, Piemontese L, Mitro N, Azzariti A, et al.
J Med Chem
. 2011 Nov;
55(1):37-54.
PMID: 22081932
A series of ureidofibrate-like derivatives was prepared and assayed for their PPAR functional activity. A calorimetric approach was used to characterize PPARγ-ligand interactions, and docking experiments and X-ray studies were...
7.
Azzariti A, Bocci G, Porcelli L, Fioravanti A, Sini P, Simone G, et al.
Br J Cancer
. 2011 Feb;
104(5):769-80.
PMID: 21304529
Background: AZD1152, the prodrug for AZD1152-hydroxyquinazoline pyrazol anilide (HQPA), is a selective inhibitor of Aurora B kinase activity. Preclinical evaluation of AZD1152 has been reported in several human cancer models....
8.
Sebastian S, Azzariti A, Accardi R, Conti D, Pilato B, Lacalamita R, et al.
Int J Mol Med
. 2008 May;
21(6):809-17.
PMID: 18506376
Recently improved understanding of the pathogenesis of human head and neck squamous cell carcinoma (HNSCC) has led to the development of new, molecular-based therapeutic strategies, one of the more promising...
9.
Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A
Br J Cancer
. 2004 Nov;
91(11):1964-9.
PMID: 15545972
Prognosis and survival of patients with hepatocellular carcinoma (HCC) is still very poor, and no therapies are currently available to inhibit tumour growth and metastases. Recently, we reported that the...
10.
Travis J, Giles P, Porcelli L, Reilly C, Baugh R, Powers J
Ciba Found Symp
. 1979 Jan;
(75):51-68.
PMID: 399898
Two of the major enzymes present in an released from neutrophil granulocytes are the endoproteinases elastase and cathepsin G. While the former is believed to be one of the major...